A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer

Clinical Trial ID NCT01804465

PubWeight™ 22.12‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01804465

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
2 Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013 1.09
3 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
4 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
5 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
6 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
7 Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol 2014 0.92
8 AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev 2014 0.91
9 Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology 2014 0.90
10 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
11 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
12 Immunotherapy for solid tumors--a review for surgeons. J Surg Res 2013 0.83
13 Improving the clinical impact of biomaterials in cancer immunotherapy. Oncotarget 2016 0.83
14 Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother 2015 0.82
15 Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evid 2014 0.81
16 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
17 New drugs in prostate cancer. Prostate Int 2016 0.80
18 Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med 2016 0.78
19 Immunotherapy for prostate cancer: False promises or true hope? Cancer 2016 0.78
20 The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. Rev Urol 2014 0.77
21 Immune Therapy for Prostate Cancer. Cancer J 2016 0.76
22 Immunotherapy in genitourinary malignancies. Curr Opin Urol 2016 0.75
23 Evaluating immune responses after sipuleucel-T therapy. Cancer Biol Ther 2015 0.75
24 A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) 2016 0.75
25 Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. P T 2014 0.75
26 Immune Checkpoint Therapies in Prostate Cancer. Cancer J 2016 0.75
Next 100